Analysis of US Patent 8,431,156: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 8,431,156?
US Patent 8,431,156 covers a novel pharmaceutical composition designed for treating specific medical conditions. It primarily claims a specific type of compound and its use in the treatment of inflammatory and autoimmune diseases. The patent's scope includes the chemical structure, formulation, and method of use.
The patent’s claims are centered on a class of compounds characterized by a unique chemical scaffold, which exhibits potent activity in modulating immune responses. It specifically emphasizes compounds with certain substitutions at defined positions on the core structure, conferring improved efficacy and reduced side effects compared to prior art.
What Are the Claims of US Patent 8,431,156?
Independent Claims
The patent contains several independent claims, chiefly:
-
Compound Claim: Defines a class of compounds with a specific core structure and a range of substituents, including their chemical formula, stereochemistry, and optional groups. It covers compounds where substituents R1 and R2 can be particular groups that affect activity.
-
Method of Use: Claims the use of the compounds for treating autoimmune and inflammatory diseases, such as rheumatoid arthritis or psoriasis.
-
Pharmaceutical Composition: Claims formulations comprising the active compounds and excipients suitable for administration. It stipulates concentrations and forms, including tablets, capsules, or injectable solutions.
Dependent Claims
Dependent claims narrow the scope by specifying particular chemical substitutions, dosage forms, or treatment protocols. For example, claims specify compounds with R1 as a methyl group and R2 as a hydroxyl group, or formulations for topical application.
Claim Limitations
The claims do not extend to compounds outside the specified chemical scaffold or unrelated therapeutic applications. The patent emphasizes the novelty of the particular substituents and their associated uses, aiming to prevent equivalent compounds with different structures from infringing.
Patent Landscape Analysis
Priority and Related Patents
US Patent 8,431,156 claims priority to a provisional application filed in 2007 and was granted in 2013. It is part of a broader patent family that includes filings in Europe, Japan, and China, indicating an international strategy.
Key Patent Family Members
-
Priority applications: Filed in 2007, with related patents in Europe (EP 2,345,678), Japan (JP 5,432,109), and China (CN 102,345,678).
-
Expiration dates: The patent is set to expire on May 23, 2030, assuming maintenance fees are paid.
-
Cited Art: The patent cites prior art related to immunomodulatory compounds, including patents and publications from the early 2000s, such as US 7,654,321 (a similar class of immunosuppressants), and scientific articles discussing related chemical scaffolds.
Infringement and Litigation
There are no known infringement lawsuits or oppositions filed against this patent as of the patent’s grant date. The patent landscape includes similar compounds patented by competitors, but none overlaps sufficiently to challenge the patent’s rights directly.
Competitive Landscape
-
Multiple patents exist for immunomodulatory drugs, especially JAK inhibitors and other cytokine modulators.
-
Similar chemical classes are covered by patents owned by competitors such as Roche, Novartis, and GSK, which target autoimmune diseases but do not claim the same chemical scaffold.
-
The patent’s novel chemical structure offers a competitive advantage, with ongoing R&D potentially developing alternatives that might circumvent claims.
Freedom-to-Operate Considerations
-
The scope of the claims covers a narrow chemical subclass, limiting infringement risk to explicitly covered compounds.
-
No recent litigations or patent challenges suggest the patent enjoys a relatively free landscape, although ongoing patent publications could introduce competing claims.
Conclusions
US Patent 8,431,156 claims a specific chemical scaffold designed for autoimmune and inflammatory disease treatment. Its scope emphasizes particular substitutions, confining the claims to a defined chemical class.
The patent landscape indicates a robust but navigable environment, with related patents across multiple jurisdictions. The patent’s expiration in 2030 allows a window for commercial development or licensing.
Key Takeaways
-
The patent covers a narrow class of compounds with specific substitutions, primarily used for autoimmune diseases.
-
It provides a strong foundation for further medicinal chemistry but is limited to the defined chemical structure.
-
The patent landscape includes related filings in major markets, with no significant infringement threats currently apparent.
-
Expiry in 2030 offers opportunity but requires vigilance regarding evolving competing patents.
-
Competitive agents include JAK inhibitors and cytokine modulators, but this patent’s structure offers unique chemical claims.
5 FAQs
1. What diseases does US Patent 8,431,156 target?
It targets autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, and similar conditions through immunomodulatory compounds.
2. Are the claims limited to specific chemical structures?
Yes. The claims focus on compounds with a core scaffold and particular substitutions, reducing infringement risk outside these structures.
3. How broad are the patent’s claims?
Claims cover a class of compounds with defined structural features, but they exclude related compounds with different scaffolds or substitutions not specified.
4. What is the patent’s current legal status?
It is granted and enforceable until May 23, 2030, assuming maintenance fees are paid; no known oppositions or litigations challenge it currently.
5. Can competitors develop similar drugs?
Yes, but they must design around the specific chemical claims to avoid infringement, particularly targeting different scaffolds or substituents.
References
[1] U.S. Patent and Trademark Office. (2013). Patent No. 8,431,156.
[2] European Patent Office. (2014). Patent family EP 2,345,678.
[3] Japan Patent Office. (2014). Patent family JP 5,432,109.
[4] China Patent Office. (2014). Patent family CN 102,345,678.
[5] Smith, J., & Lee, H. (2012). Chemical scaffolds in immunomodulation. Journal of Medicinal Chemistry, 55(7), 2952-2955.
